<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>2425</id>
    <completedYear>2020</completedYear>
    <publishedYear>2020</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>2</pageFirst>
    <pageLast>16</pageLast>
    <pageNumber>16</pageNumber>
    <edition/>
    <issue>1</issue>
    <volume>8</volume>
    <type>article</type>
    <publisherName>MDPI AG</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Health economic evaluation of gene replacement therapies: methodological issues and recommendations</title>
    <parentTitle language="eng">Journal of Market Access &amp; Health Policy</parentTitle>
    <identifier type="issn">2001-6689</identifier>
    <identifier type="doi">10.1080/20016689.2020.1822666</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T12:18:58Z","timestamp":1725452338649},"reference-count":99,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"unspecified","delay-in-days":283,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Gene Therapies","award":["na"]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Market Access &amp;amp; Health Policy"],"published-print":{"date-parts":[[2020,1,1]]},"DOI":"10.1080\/20016689.2020.1822666","type":"journal-article","created":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T18:02:08Z","timestamp":1602439328000},"page":"1822666","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Health economic evaluation of gene replacement therapies: methodological issues and recommendations"],"prefix":"10.3390","volume":"8","author":[{"given":"Samuel","family":"Aball\u00e9a","sequence":"first","affiliation":[{"name":"Creativ-Ceutical, HEOR, Rotterdam, Netherlands"}]},{"given":"Katia","family":"Thokagevistk","sequence":"additional","affiliation":[{"name":"Creativ-Ceutical, HEOR, Paris, France"}]},{"given":"Rimma","family":"Velikanova","sequence":"additional","affiliation":[{"name":"Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology &amp; Economics, University of Groningen, Groningen, Netherlands"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium"}]},{"given":"Lieven","family":"Annemans","sequence":"additional","affiliation":[{"name":"Department of Public Health, Ghent University, Ghent, Belgium"}]},{"given":"Fernando","family":"Antonanzas","sequence":"additional","affiliation":[{"name":"Department of Economics, University of La Rioja, Logro\u00f1o, Spain"}]},{"given":"Pascal","family":"Auquier","sequence":"additional","affiliation":[{"name":"CEReSS - Health Service Research and Quality of Life Center, Aix-Marseille University, Marseille, France"}]},{"given":"Cl\u00e9ment","family":"Fran\u00e7ois","sequence":"additional","affiliation":[{"name":"Creativ-Ceutical, HEOR, Paris, France"},{"name":"Public Health Department - Research Unit, Aix-Marseille University, Marseille, France"}]},{"given":"Frank-Ulrich","family":"Fricke","sequence":"additional","affiliation":[{"name":"Technische Hochschule N\u00fcrnberg, N\u00fcrnberg, Germany"}]},{"given":"Daniel","family":"Malone","sequence":"additional","affiliation":[{"name":"Pharmacotherapy Faculty, College of Pharmacy, University of Utah, Salt Lake City, USA"}]},{"given":"Aur\u00e9lie","family":"Millier","sequence":"additional","affiliation":[{"name":"Creativ-Ceutical, HEOR, Paris, France"}]},{"given":"Ulf","family":"Persson","sequence":"additional","affiliation":[{"name":"The Swedish Institute for Health Economics (IHE), Lund, Sweden"}]},{"given":"Stavros","family":"Petrou","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}]},{"given":"Omar","family":"Dabbous","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research and Real World EvidenceAveXis Inc, Novartis Gene Therapies, Bannockburn, IL, USA"}]},{"ORCID":"http:\/\/orcid.org\/0000-0002-6306-3653","authenticated-orcid":false,"given":"Maarten","family":"Postma","sequence":"additional","affiliation":[{"name":"Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology &amp; Economics, University of Groningen, Groningen, Netherlands"}]},{"ORCID":"http:\/\/orcid.org\/0000-0001-7939-7204","authenticated-orcid":false,"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[{"name":"Creativ-Ceutical, HEOR, Paris, France"},{"name":"Public Health Department - Research Unit, Aix-Marseille University, Marseille, France"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,11]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38326"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.11.007"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.2174\/1389201019666180619151413"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0068"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4672"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-018-1007-x"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.3310\/hta21070"},{"key":"cit0008","unstructured":"Marsden G, Towse A Exploring the assessment and appraisal of regenerative medicines and cell therapy products: is the NICE approach fit for purpose? 2017. [cited May 2019]. Available from: https:\/\/www.ohe.org\/publications\/exploring-assessment-and-appraisal-regenerative-medicines-and-cell-therapy-products#"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.2841"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-018-0102-3"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.2512"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1601484"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018021345"},{"key":"cit0014","unstructured":"ICER. Voretigene neparvovec for biallelic RPE65-mediated retinal disease: effectiveness and value; 2017. [cited 2019 Jun 6]. Available from: https:\/\/icer-review.org\/wp-content\/uploads\/2017\/06\/MWCEPAC_VORETIGENE_DRAFT_EVIDENCE_REPORT_11152017.pdf"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.03.012"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"cit0017","unstructured":"ICER. ICER\u2019s reference case for economic evaluations: principles and rationale; 2018. [cited 2019 Jun 6]. Available from: https:\/\/icer-review.org\/wp-content\/uploads\/2018\/07\/ICER_Reference_Case_July-2018.pdf"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0695-0"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.rasd.2010.10.004"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-2127"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6858.875"},{"first-page":"68","volume-title":"Economic evaluation in health care: merging theory with practice","year":"2002","author":"Brouwer W","key":"cit0022"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0468-y"},{"issue":"3","key":"cit0024","first-page":"127","volume":"13","author":"Hjortsberg C","year":"2010","journal-title":"J Ment Health Policy Econ"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-018-0976-0"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0749-8"},{"issue":"1","key":"cit0027","volume":"4","author":"Hanna E","year":"2016","journal-title":"J Mark Access Health Policy"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1177\/0883073813495959"},{"key":"cit0029","unstructured":"Gene replacement therapy clinical trial for patients with spinal muscular atrophy Type 1 (STR1VE) [updated Nov 2019; cited Nov 2019]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03306277"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.10.011"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1503\/cjs.013916"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.1398"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.1915"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.12.011"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1214\/09-STS313"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldq033"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.10.007"},{"key":"cit0038","unstructured":"FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality; 2019. [cited November 2019]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2006.9.716"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1618661"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-79"},{"key":"cit0042","unstructured":"The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective - 2003 Evidence from the EuroQol BIOMED Research Programme. Springer, 2003."},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(01)00130-8"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.2165\/11591570-000000000-00000"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-0971-1"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.07.011"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0286-7"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2015.12.021"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.02.011"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-014-0168-2"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199902000-00003"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S214084"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-313089"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.014"},{"key":"cit0055","unstructured":"US Department of Health and Human Services. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims; 2009. [cited November 2019]. Available from: https:\/\/www.fda.gov\/media\/77832\/download"},{"key":"cit0056","unstructured":"European Medicines Agency. Committee for medicinal products for human use. Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. [cited November 2019.]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003637.pdf"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0404-1"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/S1574-0064(00)80045-1"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9501500302"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00516.x"},{"key":"cit0061","unstructured":"NICE. Guide to the methods of technology appraisal. Process and methods [PMG9]; 2013."},{"key":"cit0062","unstructured":"HAS. Choices in methods for economic evaluation. A methodological guide; 2012. [cited 2019 Jun 6]. Available from: https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2012-10\/choices_in_methods_for_economic_evaluation.pdf"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.12.007"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200624110-00004"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.12.009"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(99)00174-4"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2018.04.001"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2015.1039519"},{"volume-title":"Public preferences for health gains and cures: a discrete choice experiment","year":"2019","author":"Hampson G","key":"cit0069"},{"key":"cit0070","unstructured":"NICE and NHS England consultation on changes to the arrangements for evaluating and funding drugs and other health technologies assessed through NICE\u2019s technology appraisal and highly specialised technologies programmes; 2017. [cited December 2019]. Available from: https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/board-paper-TA-HST-consultation-mar-17-HST-only.pdf"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1299665"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.06.014"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(02)00101-6"},{"key":"cit0074","unstructured":"EurVaQ. European value of a quality adjusted life year. Instrument: specific targeted research project. Final publishable report. Sixth framework programme. [cited November 2019]. Available from: https:\/\/research.ncl.ac.uk\/eurovaq\/EuroVaQ_Final_Publishable_Report_and_Appendices.pdf"},{"volume-title":"Methods for the economic evaluation of health care programmes","year":"2015","author":"Drummond MF","key":"cit0075"},{"edition":"2","volume-title":"Peter J Neumann; Theodore G Ganiats; Louise B Russell; Gillian D Sanders; Joanna E Siegel. Cost-effectiveness in health and medicine","year":"2017","key":"cit0076"},{"key":"cit0077","unstructured":"Choix m\u00e9thodologiques pour l\u2019\u00e9valuation de l\u2019efficience \u00e0 la HAS: version soumise \u00e0 la consultation publique \u2013 HAS (11 juin 2019); 2019. [cited November 2019]. Available from: http:\/\/www.ors-auvergne.org\/veille-sante-social\/choix-methodologiques-levaluation-de-lefficience-a-has-version-soumise-a-consultation-publique-has-11-juin-2019\/"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1016\/j.csda.2007.04.018"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0186-3"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.01.019"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4288"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00709.x"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2017.02110"},{"key":"cit0084","unstructured":"Discounting for public policy: theory and recent evidence on the merits of updating the discount rate: council of economic advisers issue brief; 2017. [cited November 2019]. Available from: https:\/\/obamawhitehouse.archives.gov\/sites\/default\/files\/page\/files\/201701_cea_discounting_issue_brief.pdf"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2004.74002.x"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.2167"},{"key":"cit0087","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/oso\/9780195108248.003.0007","volume-title":"Cost-effectiveness. Heal. Med","author":"Lipscomb J","year":"1996"},{"key":"cit0088","unstructured":"Cleemput I, Neyt M, Van De Sande S, et al. Belgian guidelines for economic evaluations and budget impact analyses: second edition. KCE reports. Brussels: Belgian Health Care Knowledge Centre; 2012. [cited May 2018]. Available from: https:\/\/kce.fgov.be\/sites\/default\/files\/page_documents\/KCE_183C_economic_evaluations_second_edition.pdf"},{"key":"cit0089","unstructured":"National Health Care Institute. Guideline for economic evaluations in healthcare. Diemen; 2016. [cited May 2018]. Available from: https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2016\/06\/16\/guideline-foreconomic-evaluations-in-healthcare"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197703312961304"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.29.3.300"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1612"},{"issue":"3","key":"cit0093","first-page":"364","volume":"60","author":"Arrow K","year":"1970","journal-title":"Am Econ Rev"},{"key":"cit0094","unstructured":"Bloomberg. Government bond rates overview; 2020. [cited 2020 June 10]. Available from: https:\/\/www.bloomberg.com\/markets\/rates-bonds\/government-bonds\/us"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.5.1.59"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7514.446"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1002\/hec.618"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0335-2"},{"key":"cit0099","unstructured":"WHO guide for standardization of economic evaluations of immunization programmes; 2019."}],"container-title":["Journal of Market Access &amp;amp; Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20016689.2020.1822666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T20:05:50Z","timestamp":1723752350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/search?q=10.1080\/20016689.2020.1822666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,1]]}},"alternative-id":["10.1080\/20016689.2020.1822666"],"URL":"http:\/\/dx.doi.org\/10.1080\/20016689.2020.1822666","relation":{},"ISSN":["2001-6689"],"issn-type":[{"type":"electronic","value":"2001-6689"}],"subject":[],"published":{"date-parts":[[2020,1,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims &amp; Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&amp;journalCode=zjma20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&amp;journalCode=zjma20","order":2,"name":"aims_and_scope_url","label":"Aim &amp; Scope"},{"value":"2020-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">http://creativecommons.org/licenses/by-nc/4.0/</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PersonAuthorFirstName_6,PersonAuthorLastName_6,PersonAuthorFirstName_7,PersonAuthorLastName_7,PersonAuthorFirstName_8,PersonAuthorLastName_8,PersonAuthorFirstName_9,PersonAuthorLastName_9,PersonAuthorFirstName_10,PersonAuthorLastName_10,PersonAuthorFirstName_11,PersonAuthorLastName_11,PersonAuthorFirstName_12,PersonAuthorLastName_12,PersonAuthorFirstName_13,PersonAuthorLastName_13,PersonAuthorFirstName_14,PersonAuthorLastName_14,PersonAuthorFirstName_15,PersonAuthorLastName_15,PersonAuthorIdentifierOrcid_15,PersonAuthorFirstName_16,PersonAuthorLastName_16,PersonAuthorIdentifierOrcid_16,PublisherName,TitleMain_1,Language,TitleParent_1,ArticleNumber,Issue,Volume,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="Reviewstatus">Begutachtet/Reviewed</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">false</enrichment>
    <licence>Creative Commons - CC BY-NC - Namensnennung - Nicht kommerziell 4.0 International</licence>
    <author>Samuel Aballéa</author>
    <author>Katia Thokagevistk</author>
    <author>Rimma Velikanova</author>
    <author>Steven Simoens</author>
    <author>Lieven Annemans</author>
    <author>Fernando Antonanzas</author>
    <author>Pascal Auquier</author>
    <author>Clément François</author>
    <author>Frank-Ulrich Fricke</author>
    <author>Daniel Malone</author>
    <author>Aurélie Millier</author>
    <author>Ulf Persson</author>
    <author>Stavros Petrou</author>
    <author>Omar Dabbous</author>
    <author>Maarten Postma</author>
    <author>Mondher Toumi</author>
    <subject>
      <language>deu</language>
      <type>uncontrolled</type>
      <value>Gene replacement therapy; guidelines; health economic evaluation; methods; cost- effectiveness analysis; QALY</value>
    </subject>
    <collection role="institutes" number="">Fakultät Betriebswirtschaft</collection>
  </doc>
</export-example>
